Zacks Investment Research Upgrades Xencor (XNCR) to “Buy”

Xencor (NASDAQ:XNCR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Saturday. The brokerage presently has a $43.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 14.39% from the stock’s current price.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Other equities analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Xencor from a “hold” rating to a “buy” rating in a research report on Friday, November 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $40.00 price objective on shares of Xencor in a research report on Tuesday, November 6th. BTIG Research started coverage on shares of Xencor in a research report on Monday, September 10th. They set a “buy” rating and a $56.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of Xencor in a research report on Monday, October 8th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $41.71.

NASDAQ XNCR traded down $0.88 on Friday, hitting $37.59. 186,654 shares of the stock were exchanged, compared to its average volume of 150,300. Xencor has a 52-week low of $19.89 and a 52-week high of $48.38. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -35.80 and a beta of 1.79.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.57. The firm had revenue of $29.04 million for the quarter. On average, equities research analysts expect that Xencor will post -1.53 earnings per share for the current fiscal year.

In other news, insider Paul A. Foster sold 40,000 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $46.03, for a total transaction of $1,841,200.00. Following the transaction, the insider now directly owns 44,952 shares in the company, valued at approximately $2,069,140.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder John S. Stafford III sold 1,000 shares of the business’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $48.05, for a total transaction of $48,050.00. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.

A number of large investors have recently modified their holdings of XNCR. Sei Investments Co. bought a new stake in Xencor in the second quarter worth $138,000. Tower Research Capital LLC TRC bought a new stake in Xencor in the third quarter worth $142,000. Public Employees Retirement Association of Colorado boosted its holdings in Xencor by 64.7% in the third quarter. Public Employees Retirement Association of Colorado now owns 4,404 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 1,730 shares in the last quarter. UBS Group AG boosted its holdings in Xencor by 449.9% in the first quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 4,886 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in Xencor in the second quarter worth $232,000. Hedge funds and other institutional investors own 82.17% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Recommended Story: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply